IB 
Union Calendar No. 434 
113TH CONGRESS 
2D SESSION 
H. R. 4771 
[Report No. 113–587, Parts I and II] 
To amend the Controlled Substances Act to more effectively regulate anabolic 
steroids. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 29, 2014 
Mr. PITTS (for himself and Mr. PALLONE) introduced the following bill; which 
was referred to the Committee on Energy and Commerce, and in addition 
to the Committee on the Judiciary, for a period to be subsequently deter-
mined by the Speaker, in each case for consideration of such provisions 
as fall within the jurisdiction of the committee concerned 
SEPTEMBER 15, 2014 
Additional sponsors: Mr. CHAFFETZ, Mr. BEN RAY LUJA´N of New Mexico, 
Ms. SHEA-PORTER, Mr. AMODEI, and Ms. DUCKWORTH 
SEPTEMBER 15, 2014 
Reported from the Committee on Energy and Commerce with an amendment 
[Strike out all after the enacting clause and insert the part printed in italic] 
SEPTEMBER 15, 2014 
Reported from the Committee on the Judiciary with an amendment; com-
mitted to the Committee of the Whole House on the State of the Union 
and ordered to be printed 
[Strike out all after the enacting clause and insert the part printed in boldface roman] 
[For text of introduced bill, see copy of bill as introduced on May 29, 2014] 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6652
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
A BILL 
To amend the Controlled Substances Act to more effectively 
regulate anabolic steroids. 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6652
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Designer Anabolic Ster-
oid Control Act of 2014’’. 
SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 
ACT. 
(a) DEFINITIONS.—Section 102(41) of the Controlled 
Substances Act (21 U.S.C. 802(41)) is amended— 
(1) in subparagraph (A)— 
(A) in clause (xlix), by striking ‘‘and’’ at 
the end; 
(B) by redesignating clause (xlx) as clause 
(lxxv); and 
(C) by inserting after clause (xlix) the fol-
lowing: 
‘‘(l) 5α-Androstan-3,6,17-trione; 
‘‘(li) 6-bromo-androstan-3,17-dione; 
‘‘(lii) 6-bromo-androsta-1,4-diene-3,17-dione; 
‘‘(liii) 
4-chloro-17α-methyl-androsta-1,4-diene- 
3,17β-diol; 
‘‘(liv) 4-chloro-17α-methyl-androst-4-ene-3β,17β- 
diol; 
‘‘(lv) 4-chloro-17α-methyl-17β-hydroxy-androst- 
4-en-3-one; 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6203
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
‘‘(lvi) 4-chloro-17α-methyl-17β-hydroxy-androst- 
4-ene-3,11-dione; 
‘‘(lvii) 
4-chloro-17α-methyl-androsta-1,4-diene- 
3,17β-diol; 
‘‘(lviii) 
2α,17α-dimethyl-17β-hydroxy-5α- 
androstan-3-one; 
‘‘(lix) 
2α,17α-dimethyl-17β-hydroxy-5β- 
androstan-3-one; 
‘‘(lx) 
2α,3α-epithio-17α-methyl-5α-androstan- 
17β-ol; 
‘‘(lxi) [3,2-c]-furazan-5α-androstan-17β-ol; 
‘‘(lxii) 3β-hydroxy-estra-4,9,11-trien-17-one; 
‘‘(lxiii) 17α-methyl-androst-2-ene-3,17β-diol; 
‘‘(lxiv) 17α-methyl-androsta-1,4-diene-3,17β-diol; 
‘‘(lxv) Estra-4,9,11-triene-3,17-dione; 
‘‘(lxvi) 18a-Homo-3-hydroxy-estra-2,5(10)-dien- 
17-one; 
‘‘(lxvii) 6α-Methyl-androst-4-ene-3,17-dione; 
‘‘(lxviii) 17α-Methyl-androstan-3-hydroxyimine- 
17β-ol; 
‘‘(lxix) 17α-Methyl-5α-androstan-17β-ol; 
‘‘(lxx) 17β-Hydroxy-androstano[2,3-d]isoxazole; 
‘‘(lxxi) 17β-Hydroxy-androstano[3,2-c]isoxazole; 
‘‘(lxxii) 4-Hydroxy-androst-4-ene-3,17-dione[3,2- 
c]pyrazole-5α-androstan-17β-ol; 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6203
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
‘‘(lxxiii) [3,2-c]pyrazole-androst-4-en-17β-ol; 
‘‘(lxxiv) 
[3,2-c]pyrazole-5α-androstan-17β-ol; 
and’’; and 
(2) by adding at the end the following: 
‘‘(C)(i) Subject to clause (ii), a drug or hor-
monal substance (other than estrogens, progestins, 
corticosteroids, and dehydroepiandrosterone) that is 
not listed in subparagraph (A) and is derived from, 
or has a chemical structure substantially similar to, 
1 or more anabolic steroids listed in subparagraph 
(A) shall be considered to be an anabolic steroid for 
purposes of this Act if— 
‘‘(I) the drug or substance has been created 
or manufactured with the intent of producing a 
drug or other substance that either— 
‘‘(aa) promotes muscle growth; or 
‘‘(bb) otherwise causes a pharma-
cological effect similar to that of testos-
terone; or 
‘‘(II) the drug or substance has been, or is 
intended to be, marketed or otherwise promoted 
in any manner suggesting that consuming it will 
promote muscle growth or any other pharma-
cological effect similar to that of testosterone. 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6203
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
‘‘(ii) A substance shall not be considered to be a 
drug or hormonal substance for purposes of this sub-
paragraph if it— 
‘‘(I) is— 
‘‘(aa) an herb or other botanical; 
‘‘(bb) a concentrate, metabolite, or ex-
tract of, or a constituent isolated directly 
from, an herb or other botanical; or 
‘‘(cc) a combination of 2 or more sub-
stances described in item (aa) or (bb); 
‘‘(II) is a dietary ingredient for purposes of 
the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 301 et seq.); and 
‘‘(III) is not anabolic or androgenic. 
‘‘(iii) In accordance with section 515(a), any 
person claiming the benefit of an exemption or excep-
tion under clause (ii) shall bear the burden of going 
forward with the evidence with respect to such exemp-
tion or exception.’’. 
(b) CLASSIFICATION AUTHORITY.—Section 201 of the 
Controlled Substances Act (21 U.S.C. 811) is amended by 
adding at the end the following: 
‘‘(i) TEMPORARY AND PERMANENT SCHEDULING OF 
RECENTLY EMERGED ANABOLIC STEROIDS.— 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6203
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
‘‘(1) The Attorney General may issue a tem-
porary order adding a drug or other substance to the 
definition of anabolic steroids if the Attorney General 
finds that— 
‘‘(A) the drug or other substance satisfies 
the criteria for being considered an anabolic ster-
oid under section 102(41) but is not listed in 
that section or by regulation of the Attorney 
General as being an anabolic steroid; and 
‘‘(B) adding such drug or other substance to 
the definition of anabolic steroids will assist in 
preventing abuse or misuse of the drug or other 
substance. 
‘‘(2) An order issued under paragraph (1) shall 
not take effect until 30 days after the date of the pub-
lication by the Attorney General of a notice in the 
Federal Register of the intention to issue such order 
and the grounds upon which such order is to be 
issued. The order shall expire not later than 24 
months after the date it becomes effective, except that 
the Attorney General may, during the pendency of 
proceedings under paragraph (6), extend the tem-
porary scheduling order for up to 6 months. 
‘‘(3) The Attorney General shall transmit notice 
of an order proposed to be issued under paragraph (1) 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6203
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS